BRAF and metastatic malignant neoplasm in the lymph nodes: Importantly, many studies have proved that BRAF mutation is correlated with high-risk clinicopathological characteristics, such as larger tumor size, extrathyroidal invasion, local lymph node metastasis, distant metastasis, and advanced disease stages, suggesting that it is not only an independent oncogenic event for PTC tumorigenesis, but also involved in progression of PTC [14–16].